(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up to 1 billion pounds ($1.33 billion) over the next ten years to broaden ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a fresh partner in mRNA specialist BioNTech. BioNTech plans to invest up to ...

an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1 st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech’s ...

German multinational biotechnology company BioNTech is preparing to establish its Cambridge R&D centre at 1 Discovery Drive ...

The United Kingdom government has announced its plan to accelerate research into mRNA cancer vaccines in an agreement signed with pharmaceutical company BioNTech. The United Kingdom has signed ...

BioNTech also expects new private markets to open up in places like the United Kingdom this year, Richardson noted. For the full year, BioNTech is sticking by its revenue forecast of 2.5 billion ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

Overall, BioNTech reported total revenues of € ... European Union and received approval for the same vaccine in the United Kingdom. Over in the United States, BioNTech has initiated a rolling ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

US pharma major Bristol Myers Squibb (NYSE: BMY) has entered into an agreement for the global co-development and ...